Day2 Day 4 Cell line 5 µl/ml 10 µl/ml 5 µl/ml 10 µl/ml HBEC4 103.2 ± 10.1 44.5 ± 8.5 99.6 ± 15.2 29.9 ± 5.3 H661 38.2 ± 9.2 0.0 ± 0.0 23.3 ± 3.8 0.0 ± 0.0 H838 51.8 ± 4.4 16.0 ± 1.0 62.1 ± 1.5 12.1 ± 3.0 H1299 56.2 ± 9.2 0.0 ± 0.0 40.2 ± 1.8 0.0 ± 0.0 H157 54.5 ± 6.2 23.1 ± 6.6 47.9 ± 11.5 14.2 ± 5.3 H1395 77.3 ± 4.9 40.8 ± 7.9 74.9 ± 5.1 29.6 ± 4.6 H1792 82.7 ± 4.2 48.5 ± 11.6 73.8 ± 4.7 36.3 ± 7.1 HCC827 83.8 ± 8.4 63.8 ± 11.6 66.3 ± 11.3 48.1 ± 5.6 H441 93.8 ± 11.7 67.8 ± 11.4 77.4 ± 10.9 56.9 ± 12.9 H460 84.8 ± 11.8 80.0 ± 10.1 93.0 ± 17.0 79.8 ± 19.6

Table 1: The percentage of viable cells after MK615 treatment in nine NSCLC cell lines and the HBEC4 immortalized bronchial epithelial cell line.